KALA Kala BIO (KALA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001479419
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
9
13F, latest reported quarter
KALA filings, in plain words
Read the full summary
The latest 5% ownership filing is a 13D by David E. Lazar, filed 2026-02-06, for 5.2% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Kala BIO insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for KALA BIO, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Jun 24, 2025.
- The trade is 149.6% of the 103,540 shares held after it.
- 5 other insiders sold within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Iwicki Mark T sold about $125.5K of KALA on Oct 23, 2025; 5 other insiders sold within 30 days and 9 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Oct 22, 2025.
- The trade is 3.3% of the 28,906 shares held after it.
- 5 other insiders sold within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF FINANCIAL OFFICER Reumuth Mary sold about $793 of KALA on Oct 23, 2025; 5 other insiders sold within 30 days and 9 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Jun 24, 2025.
- The trade is 107.9% of the 29,873 shares held after it.
- 5 other insiders sold within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF FINANCIAL OFFICER Reumuth Mary sold about $26.8K of KALA on Oct 22, 2025; 5 other insiders sold within 30 days and 9 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Jun 24, 2025.
- The trade is 132.9% of the 35,932 shares held after it.
- 5 other insiders sold within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Bazemore Todd sold about $39.6K of KALA on Oct 22, 2025; 5 other insiders sold within 30 days and 9 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Jun 24, 2025.
- The trade is 130.0% of the 35,952 shares held after it.
- 5 other insiders sold within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SEE REMARKS Brazzell Romulus K sold about $38.8K of KALA on Oct 22, 2025; 5 other insiders sold within 30 days and 9 funds added in the latest 13F quarter.74 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
9 funds bought in last quarter
below 86% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
2.8% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 61% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch KALA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-99.5%12M
Insider sell13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns KALA: institutional holders (13F)
13F holdings, latest reported quarter
220,623 sh
$381.7K
145,152 sh
$251.1K
101,396 sh
$175.4K
88,570 sh
$153.2K
71,542 sh
$123.8K
Congress trades in KALA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
David E. Lazar
Activist 13D · 2026-02-06
5.18%
KALA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
KALA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
VANGUARD EXTENDED MARKET INDEX FUND
$381.7K position · as of 2026-06-30
0.0%
Total Stock Market Index Trust
$614 position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$12.6K position · as of 2026-05-31
0.0%
Fidelity Extended Market Index Fund
$8.5K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$526 position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$339 position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$906.6K
-$1.0M
$2.4M
-99%
n/a
2024
$1.5M
$1.3M
$935.1K
-93%
n/a
2023
$8.3M
$3.7M
$2.9M
-98%
n/a
2022
$1.9M
$1.2M
$1.0M
-89%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 9 funds added last quarter. Each figure is a federal filing, dated the day it went public.
KALA financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.9M
four quarters, 2022-01-01 to 2022-12-31
Revenue, TTM KALA
| FY Dec 2025 | $3.9M |
| FY Dec 2024 | $3.9M |
| FY Dec 2023 | $3.9M |
| FY Dec 2022 | $3.9M |
| FY Dec 2021 | $11.2M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
-259.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM KALA
| FY Dec 2025 | -693.2% |
| FY Dec 2024 | -989.5% |
| FY Dec 2023 | -1,084% |
| FY Dec 2022 | -1,152% |
| FY Dec 2021 | -1,269% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Free cash flow, TTM KALA
| FY Dec 2025 | n/a |
| FY Dec 2024 | -$31.0M |
| FY Dec 2023 | -$29.6M |
| FY Dec 2022 | -$80.6M |
| FY Dec 2021 | -$109.9M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
2.98x
LongTermDebt as filed 2025-09-30 (9 months older than the period end) (includes the current portion); equity 2026-06-30
Debt to equity KALA
| FY Dec 2025 | 3.85x |
| FY Dec 2024 | 2.47x |
| FY Dec 2023 | 5.22x |
| FY Dec 2022 | 2.26x |
| FY Dec 2021 | 4.90x |
| Jun 2026 | 2.98x |
| Mar 2026 | 2.50x |
| Dec 2025 | 3.85x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | 5.37x |
| Dec 2024 | 2.47x |
| Sep 2024 | 5.12x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
needs four quarters of operating cash flow
Cash flow to debt KALA
| FY Dec 2025 | n/a |
| FY Dec 2024 | -0.97x |
| FY Dec 2023 | -0.71x |
| FY Dec 2022 | -1.84x |
| FY Dec 2021 | -1.32x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -1.52x |
| Jun 2025 | -1.23x |
| Mar 2025 | -0.89x |
| Dec 2024 | -0.97x |
| Sep 2024 | -0.92x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-345.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity KALA
| FY Dec 2025 | -279.2% |
| FY Dec 2024 | -388.3% |
| FY Dec 2023 | -318.7% |
| FY Dec 2022 | -250.6% |
| FY Dec 2021 | -244.2% |
| Jun 2026 | -345.3% |
| Mar 2026 | -238.7% |
| Dec 2025 | -279.2% |
| Sep 2025 | n/a |
| Jun 2025 | -708.3% |
| Mar 2025 | -576.5% |
| Dec 2024 | -388.3% |
| Sep 2024 | -431.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-43.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets KALA
| FY Dec 2025 | -83.0% |
| FY Dec 2024 | -69.1% |
| FY Dec 2023 | -59.1% |
| FY Dec 2022 | -39.6% |
| FY Dec 2021 | -79.0% |
| Jun 2026 | -43.2% |
| Mar 2026 | -64.9% |
| Dec 2025 | -83.0% |
| Sep 2025 | -90.6% |
| Jun 2025 | -76.2% |
| Mar 2025 | -70.4% |
| Dec 2024 | -69.1% |
| Sep 2024 | -67.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital KALA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-144.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed KALA
| FY Dec 2025 | -172.0% |
| FY Dec 2024 | -95.2% |
| FY Dec 2023 | -73.0% |
| FY Dec 2022 | -100.2% |
| FY Dec 2021 | -86.4% |
| Jun 2026 | -144.3% |
| Mar 2026 | -168.1% |
| Dec 2025 | -172.0% |
| Sep 2025 | -338.9% |
| Jun 2025 | -131.8% |
| Mar 2025 | -119.6% |
| Dec 2024 | -95.2% |
| Sep 2024 | -101.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing KALA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$30.3M
market value at close 2026-10-26 on 2026-08-14 shares, plus LongTermDebt as filed 2025-09-30 (9 months older than the period end) (includes the current portion), minus cash 2026-06-30
Enterprise value KALA
| FY Dec 2025 | $247.6M |
| FY Dec 2024 | $1.6B |
| FY Dec 2023 | $930.9M |
| FY Dec 2022 | $2.9B |
| FY Dec 2021 | $198.1B |
| Jun 2026 | $58.9M |
| Mar 2026 | $96.2M |
| Dec 2025 | $247.6M |
| Sep 2025 | $543.0M |
| Jun 2025 | $1.5B |
| Mar 2025 | $1.8B |
| Dec 2024 | $1.6B |
| Sep 2024 | $1.3B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
FCF yield KALA
| FY Dec 2025 | n/a |
| FY Dec 2024 | -1.9% |
| FY Dec 2023 | -3.1% |
| FY Dec 2022 | -2.8% |
| FY Dec 2021 | -0.1% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -7.9% |
| Jun 2025 | -2.4% |
| Mar 2025 | -1.6% |
| Dec 2024 | -1.9% |
| Sep 2024 | -2.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing KALA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $3.9M |
| Operating income | -$39.2M | -$41.0M | -$39.7M | -$81.7M |
| Net income | -$27.0M | -$38.5M | -$42.2M | -$44.8M |
| EPS (diluted) | -3.31 | -10.15 | -17.35 | -29.48 |
| Operating cash flow | -$32.0M | -$29.4M | -$27.9M | -$78.9M |
| Cash | $7.6M | $51.2M | $50.9M | $70.5M |
| Long-term debt | n/a | $20.1M | $34.2M | $37.9M |
SEC XBRL, fiscal years, as known on 2026-10-28
KALA Stock Sonar score 4/7 axes
Find similar shapesCompareKALA ranks highest on risk and compliance (37th percentile) and profitability (25th), and lowest on financial health (6th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
